The dissolution process for Tricida is entering its concluding stages. The biotech firm, which previously filed for bankruptcy, is now focused on the final distribution of remaining assets and the settlement of outstanding legal matters. For former shareholders, this phase centers on the tangible recovery of funds from a multimillion-dollar legal settlement.
Asset Distribution and Legal Settlement Execution
A primary focus for involved parties is the execution of a class action settlement, which received judicial approval in late 2025. This agreement stemmed from allegations concerning the company’s past communications about its lead drug candidate, Veverimer, a potential treatment for chronic kidney disease. The commencement of payouts from this settlement represents one of the last steps in returning capital to eligible members of the plaintiff class.
The residual value of the liquidation trust is not static. It remains significantly contingent on potential future milestone payments. While the rights to the Veverimer compound were previously sold to Renibus Therapeutics, the trust retains claims to payments triggered by specific regulatory achievements or future sales revenue. Consequently, market observers are closely monitoring the clinical progress of Veverimer under Renibus’s development, as this will dictate the possibility of additional capital returns.
Should investors sell immediately? Or is it worth buying Tricida?
Awaiting Clinical Catalysts
With no immediate court dates on the horizon, the attention of stakeholders is firmly fixed on the advancement of Veverimer at Renibus Therapeutics. The trust is expected to provide regular updates throughout the current fiscal year regarding the status of its remaining assets and liabilities. The overarching question is whether the development program can generate capital beyond the current settlement distributions already underway.
This period marks the end of Tricida’s operational story, shifting the narrative to one of asset recovery, where any further value for claimants is directly tied to the success of the divested drug candidate in its new home.
Ad
Tricida Stock: Buy or Sell?! New Tricida Analysis from April 8 delivers the answer:
The latest Tricida figures speak for themselves: Urgent action needed for Tricida investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 8.
Tricida: Buy or sell? Read more here...
